Basic Information
RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML
INFUSION, SOLUTION CONCENTRATE
Regulatory Information
SIN16548P
July 13, 2022
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
June 4, 2025
XL01FX18
Company Information
JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD
JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD
Active Ingredients
Strength: 350mg/7ml
Detailed Information
Contraindications
**Contraindications** Hypersensitivity to the active substance(s) or to any of the excipients listed in _List of Excipients_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.
Indication Information
**Indications** RYBREVANT® is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.